HSP90β controls NLRP3 autoactivation
Gain-of-function mutations in NLRP3 are linked to cryopyrin-associated periodic syndromes (CAPS). Although NLRP3 autoinflammasome assembly triggers inflammatory cytokine release, its activation mechanisms are not fully understood. Our study used a functional genetic approach to identify regulators of NLRP3 inflammasome formation. We identified the HSP90β-SGT1 chaperone complex as crucial for autoinflammasome activation in CAPS. A deficiency in HSP90β, but not in HSP90α, impaired the formation of ASC specks without affecting the priming and expression of inflammasome components. Conversely, activating NLRP3 with stimuli such as nigericin or alum bypassed the need for SGT1 and HSP90β, suggesting the existence of alternative inflammasome assembly pathways. The role of HSP90β was further demonstrated in PBMCs derived from CAPS patients. In these samples, the pathological constitutive secretion of IL-1β could be suppressed using a pharmacological inhibitor of HSP90β. This finding underscores the potential of SGT1-HSP90β modulation as a therapeutic strategy in CAPS while preserving NLRP3's physiological functions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Science advances - 10(2024), 9 vom: 28. März, Seite eadj6289 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Spel, Lotte [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytokines |
|---|
| Anmerkungen: |
Date Completed 01.03.2024 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciadv.adj6289 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369067460 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369067460 | ||
| 003 | DE-627 | ||
| 005 | 20240301232755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciadv.adj6289 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM369067460 | ||
| 035 | |a (NLM)38416826 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Spel, Lotte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HSP90β controls NLRP3 autoactivation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Gain-of-function mutations in NLRP3 are linked to cryopyrin-associated periodic syndromes (CAPS). Although NLRP3 autoinflammasome assembly triggers inflammatory cytokine release, its activation mechanisms are not fully understood. Our study used a functional genetic approach to identify regulators of NLRP3 inflammasome formation. We identified the HSP90β-SGT1 chaperone complex as crucial for autoinflammasome activation in CAPS. A deficiency in HSP90β, but not in HSP90α, impaired the formation of ASC specks without affecting the priming and expression of inflammasome components. Conversely, activating NLRP3 with stimuli such as nigericin or alum bypassed the need for SGT1 and HSP90β, suggesting the existence of alternative inflammasome assembly pathways. The role of HSP90β was further demonstrated in PBMCs derived from CAPS patients. In these samples, the pathological constitutive secretion of IL-1β could be suppressed using a pharmacological inhibitor of HSP90β. This finding underscores the potential of SGT1-HSP90β modulation as a therapeutic strategy in CAPS while preserving NLRP3's physiological functions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Inflammasomes |2 NLM | |
| 650 | 7 | |a Interleukin-1beta |2 NLM | |
| 650 | 7 | |a NLR Family, Pyrin Domain-Containing 3 Protein |2 NLM | |
| 650 | 7 | |a HSP90AB1 protein, human |2 NLM | |
| 650 | 7 | |a NLRP3 protein, human |2 NLM | |
| 700 | 1 | |a Hou, Cyrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Theodoropoulou, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Zaffalon, Léa |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoni, Arinna |e verfasserin |4 aut | |
| 700 | 1 | |a Volpi, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Hofer, Michaël |e verfasserin |4 aut | |
| 700 | 1 | |a Gattorno, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Martinon, Fabio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science advances |d 2015 |g 10(2024), 9 vom: 28. März, Seite eadj6289 |w (DE-627)NLM247717614 |x 2375-2548 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:9 |g day:28 |g month:03 |g pages:eadj6289 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciadv.adj6289 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 9 |b 28 |c 03 |h eadj6289 | ||